La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ViewRay Gestione

Gestione criteri di controllo 1/4

ViewRay's Il CEO è Paul Ziegler, nominato in Jul2023, ha un mandato di meno di un anno. possiede direttamente 0.039% delle azioni della società, per un valore di $ 7.19. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.7 anni e 3.5 anni.

Informazioni chiave

Paul Ziegler

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.04%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Ziegler rispetto agli utili di ViewRay?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	n/a	n/a	-US$107m
Sep 30 2022	n/a	n/a	-US$107m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$109m
Dec 31 2021	US$2m	US$350k	-US$110m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Paul sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Paul con le performance aziendali.

AMMINISTRATORE DELEGATO

Paul Ziegler (50 yo)

less than a year

Mandato

US$2,028,555

Compensazione

Mr. Paul Ziegler. Jr., J.D., serves as President, Chief Executive Officer and Director at ViewRay, Inc. since July 2023 and was its Chief Commercial Officer since 2021 until July 2023 and served as its Exe...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Ziegler	President	less than a year	US$2.03m	0.039% $ 7.2
James Dempsey	Founder & Chief Scientific Officer	19.6yrs	US$1.17m	0.16% $ 29.9
Jacob Signoriello	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Drew Hill	Senior Vice President of Operations & Development	1.8yrs	Nessun dato	Nessun dato
Matt Harrison	Director of Investor Relations	no data	Nessun dato	Nessun dato
Sanket Shah	Senior VP & General Counsel	less than a year	Nessun dato	0.21% $ 38.6
Karen Hackstaff	Vice President of Marketing	no data	Nessun dato	Nessun dato
Julianne Mast	Vice President of Human Resources	less than a year	Nessun dato	Nessun dato
Martin Fuss	Chief Medical Officer	no data	Nessun dato	Nessun dato
Adam Podbelski	Senior Vice President of Commercial Operations	1.8yrs	Nessun dato	0.24% $ 44.7
Steven Annen	Senior Vice President of Global Marketing	less than a year	Nessun dato	Nessun dato
Ashley Kluth	Senior Manager of Investor Relations	no data	Nessun dato	Nessun dato

0.7yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di VRAY.Q non è considerato esperto (durata media 0.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Ziegler	President	less than a year	US$2.03m	0.039% $ 7.2
Caley Castelein	Independent Director	15.8yrs	US$212.17k	0.027% $ 5.0
B. Johnson	Independent Director	3.5yrs	US$208.00k	0.092% $ 16.8
Brian Roberts	Independent Director	7.8yrs	US$221.00k	0.065% $ 12.0
Daniel Moore	Independent Chairman	5.7yrs	US$261.00k	0.11% $ 20.0
Scott Drake	Director	5.3yrs	US$5.80m	0.32% $ 59.3
Karen Prange	Independent Director	2.3yrs	US$201.00k	0% $ 0
Stefanie Corradini	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Enis Ozyar	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
James Good	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Lauren Henke	Member of Medical Advisory Board	less than a year	Nessun dato	Nessun dato
Rupesh Kotecha	Member of Medical Advisory Board	less than a year	Nessun dato	Nessun dato

3.5yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VRAY.Q sono considerati esperti (durata media dell'incarico 3.5 anni).

ViewRay Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces CFO Changes

Insider recently bought US$117k worth of stock

President recently bought US$400k worth of stock

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?